Metabolic Reprogramming by Dual AKT/ERK Inhibition Through Imipridones Elicits Unique Vulnerabilities in Glioblastoma

PURPOSE: The goal of this study is to enhance the efficacy of imipridones, a novel class of AKT/ERK inhibitors that displayed limited therapeutic efficacy against glioblastoma. EXPERIMENTAL DESIGN: Gene set enrichment, LC/MS and extracellular flux analysis were used to determine the mechanism of act...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Ishida, Chiaki T., Zhang, Yiru, Bianchetti, Elena, Shu, Chang, Trang, Nguyen T. T., Kleiner, Giulio, Sanchez-Quintero, Maria J., Quinzii, Catarina M., Westhoff, Mike-Andrew, Karpel-Massler, Georg, Prabhu, Varun V., Allen, Joshua E., Siegelin, Markus D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6214769/
https://ncbi.nlm.nih.gov/pubmed/30037819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1040
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak